Paper Titles

Photocatalytic Splitting of Water on Cu-TiO₂ Nanotubes
p.662

Significance and Expression of Heat Shock Protein 72 and Glycoprotein96 in Human Gastroenterological Cancers
p.667

Bacterial Toxicity of Functionalized Polystyrene Latex Nanoparticles Toward Escherichia coli
p.672

Development and Antimicrobial Properties of a Composite Sorbent from Carbonized Rice Husk and Fugate of Sporogenous Bacteria
p.678

Theophylline Cocrystallized with Salicylic Acid and Picolinic Acid: Preparation and Physical Properties
p.682

Study on Syntheses and Anticoagulant Action of Rare Earth Ternary Complexes with Tryptophan and Sodium Citrate
p.689

Phytochemical Screening, Antioxidant Activity and Total Phenolic Content of Spirogyra spp.
p.693

The Structure Activity Relationship and Cytotoxicity between Stemonal and 6-Deoxyclitoriacetal
p.698

Evaluation of Crude Extracts of Mimosa pusica LINN. against Colletotrichum gloeosporioides to Control Anthracnose
p.703

HomeAdvanced Materials ResearchAdvanced Materials Research Vol. 699Theophylline Cocrystallized with Salicylic Acid...

Theophylline Cocrystallized with Salicylic Acid and Picolinic Acid: Preparation and Physical Properties

Article Preview

Abstract:

Theophylline (TP) is an oral bronchodilator medicine, used to treat respiratory diseases. The problem of TP is low aqueous solubility, slow release tablets, and solid state interconversion between anhydrous and monohydrate forms as a function of relative humidity (RH). Physicochemical properties of this medicine, including solubility, humidity sensitivity, and chemical and physical stability can be improved by cocrystallizing with another compound. Herein we present the cocrystallization of TP with salicylic acid (SA) and picolinic acid (PI). Mixtures of 2:1 TP-SA and TP-PI were screened by solvent-drop grinding, crystal growth by slow evaporation and pH control at 2.0 and 7.0, and compared to the 1:1 crystalline products of TP-SA and TP-PI. The products were characterized by XRD, FT-IR/FT-Raman, and DSC/TG. Crystals of the 1:1 TP-SA, 1:1 TP-PI, and pure TP were stored at room temperature (342 °C) with 582% RH for one month and their stability examined by FT-IR.

You might also be interested in these eBooks

Materials Science and Chemical Engineering

Info:

Periodical:

Advanced Materials Research (Volume 699)

Pages:

682-688

DOI:

https://doi.org/10.4028/www.scientific.net/AMR.699.682

Citation:

Cite this paper

Online since:

May 2013

Authors:

Somphon Weenawan, Sopita Khumponkrung, Kenneth J. Haller

Keywords:

Physical Properties, Picolinic Acid, Salicylic Acid, Theophylline, Theophylline Cocrystal

Export:

RIS, BibTeX

Price:

Permissions CCC:

Request Permissions

Permissions PLS:

Request Permissions

Сopyright:

© 2013 Trans Tech Publications Ltd. All Rights Reserved

Share:

Citation:

[1] E.H. Kerns: J. Pharm. Sci. Vol. 90 (2001), p.1838.

[2] D.J. Hauss: Adv. Drug Deliv. Rev. Vol. 59 (2007), p.667.

[3] C. Leuner and J. Dressman: Eur. J. Pharm. Biopharm. Vol. 50 (2000), p.47.

[4] T. Vasconcelos, B. Sarmento and P. Costa: Drug Discovery Today Vol. 12 (2007), p.1068.

[5] B. Rodíguez-Spong, C.P. Price, A. Jayasankar, A. J. Matzger and N. Rodríguez-Hornedo: Adv. Drug Deliv. Rev. Vol. 56 (2004), p.241.

[6] N. Blagden, M. de Matas, P.T. Gavan and P. York: Adv. Drug Deliv. Rev. Vol. 59 (2007), p.617.

[7] N. Shan and M.J. Zaworotko: Drug Discovery Today Vol. 13 (2008), p.440.

[8] N. Schultheiss and A. Newman: Cryst. Growth Des. Vol. 9 (2009), p.2950.

[9] P. Guerrieri, K. Jarring and L.S. Taylor: J. Pharm. Sci. Vol. 99 (2010), p.3719.

[10] J. Lu and S. Rohani: Organic Process Research & Development Vol. 13 (2009) p.1269.

[11] P.J. Barnes and R.A. Pauwels: Eur. Respir. J. Vol. 7 (1994), p.579.

[12] P. Montuschi: International Journal of COPD. Vol. 1 (2006), p.409.

[13] Ph. Eur., USP, JP. Theophylline Anhydrous. Technical Information. D-BASF. Pharma Ingredients. EMP 030749e-07 (January 2009).

[14] E. Suihko, J. Ketolainen, A. Poso, M. Ahlgren, J. Gynther and P. Paronen: Int. J. Pharm. Vol. 158 (1997), p.47.

DOI: 10.1016/s0378-5173(97)00239-1

[15] K. Matsuo and M. Matsuoka: Cryst. Growth Des. Vol. 7 (2007), p.411.

[16] B. Legendre and S.L. Randzio: Int. J. Pharm. Vol. 343 (2007), p.41.

[17] L. Seton, D. Khamar, I. J. Bradshaw and G. A. Hutcheon: Cryst. Growth Des. Vol. 10 (2010), p.3879.

[18] N.V. Phadnis and R. Suryanarayanan: J. Pharm. Sci. Vol. 86 (1997), p.1256.

[19] A.V. Trask, W.D. Motherwell and W. Jones: Int. J. Pharm. Vol. 320 (2006), p.114.

[20] S.L. Childs, G.P. Stahly and A. Park: Mol. Pharmaceutics, Vol. 4 (2007), p.323.

[21] J. Madarász, P. Bombicz, K. Jármi, M. Bán, G. Pokol and S. Gál: J. Therm. Anal. Calorim. Vol. 69 (2002), p.281.

DOI: 10.1023/a:1019966529819

[22] A.W. Newman, S.L. Childs and B. A. Cowans in: 14 Salt and Cocrystal Form Selection, edited by S.C. Gad, of Preclinical Development Handbook: ADME and Biopharmaceutical Properties, Wiley (2008).

DOI: 10.1002/9780470249031.ch14

[23] M. Bán, P. Bombicz and J. Madarász: J. Therm. Anal. Calorim. Vol. 95 (2009), p.895.

[24] M.A. Elbagerma, H.G.M. Edwards, T. Munshi, M.D. Hargreaves, P. Matousek and I.J. Scowen: Cryst. Growth Des. Vol. 10 (2010), p.2360.

[25] P. Koczon´, J.C. Dobrowolski, W. Lewandowski and A.P. Mazurek: J. Mol. Struct. Vol. 655 (2003), p.89.

[26] W. Somphon and K.J. Haller: J. Cryst. Growth Vol. 362 (2013), p.252.

[27] SDBS Web: http://riodb01.ibase.aist.go.jp/sdbs/cgi-bin/direct_frame_top.cgi (National Institute of Advanced Industrial Science and Technology, Access Date November 13, 2012).